Research progress on malignant tumor after lung transplantation

Li Caihan; Tang Hongtao; Xu Lin; Wang Junjie; Jiang Kaiyuan; Yan Haoji; Li Haoxuan; Zheng Xiangyun; Chen Tingting; Fu Siyi; Tian Dong

doi:10.3969/j.issn.1674-7445.2021.05.019

Volume 12 Issue 5

Sep. 2021

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2021 > 12(5): 624-629

Li Caihan, Tang Hongtao, Xu Lin, et al. Research progress on malignant tumor after lung transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(5): 624-629. doi: 10.3969/j.issn.1674-7445.2021.05.019

Citation:

Li Caihan, Tang Hongtao, Xu Lin, et al. Research progress on malignant tumor after lung transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(5): 624-629. doi: 10.3969/j.issn.1674-7445.2021.05.019

Citation:

Li Caihan, Tang Hongtao, Xu Lin, et al. Research progress on malignant tumor after lung transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(5): 624-629. doi: 10.3969/j.issn.1674-7445.2021.05.019

PDF( 848 KB)

Research progress on malignant tumor after lung transplantation

doi: 10.3969/j.issn.1674-7445.2021.05.019

Medical Imaging Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong 637000, China

More Information

Corresponding author: Tian Dong, E-mail: TianD_EATTS@nsmc.edu.cn
Received Date: 2021-04-30
Available Online: 2021-09-15
Publish Date: 2021-09-15

Abstract

Abstract

Lung transplantation has become the most effective treatment of end-stage lung diseases. Along with persistent optimization of lung transplantation technique and perioperative management, the short-term clinical efficacy after lung transplantation has been significantly improved, whereas the long-term clinical prognosis remains unoptimistic. Besides chronic lung allograft dysfunction, postoperative malignant tumors also threaten the long-term survival of the recipients. Common malignant tumors following lung transplantation include nonmelanoma skin cancer, posttransplant lymphoproliferative disease and lung cancer. After solid organ transplantation, a large majority of the recipients require lifelong immunosuppressive therapy. The intensity of immunosuppressive therapy for the lung transplant recipients is generally higher than other organ transplant recipients. Immunosuppression is the main factor which leads to the impairment of anti-tumor immune monitoring function and promotes the incidence and development of malignant tumors. In this article, the risk factors, prevention and treatment of the most common malignant tumors after lung transplantation were reviewed, aiming to provide reference for comprehensive diagnosis and treatment of malignant tumors following lung transplantation.
- Lung transplantation,
- Malignant tumor,
- Nonmelanoma skin cancer,
- Posttransplant lymphoproliferative disease,
- Lung cancer,
- Immunosuppression,
- Risk factor,
- Programmed cell death protein 1,
- Cemiplimab

FullText(HTML)

References(47)

References

[1]	Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis[J]. N Engl J Med, 1986, 314(18): 1140-1145. DOI: 10.1056/NEJM198605013141802.
[2]	CHAMBERS DC, CHERIKH WS, HARHAY MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match[J]. J Heart Lung Transplant, 2019, 38(10): 1042-1055. DOI: 10.1016/j.healun.2019.08.001.
[3]	HAYES D JR, CHERIKH WS, CHAMBERS DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty-second pediatric lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match[J]. J Heart Lung Transplant, 2019, 38(10): 1015-1027. DOI: 10.1016/j.healun.2019.08.003.
[4]	CANGEMI M, MONTICO B, FAÈ DA, et al. Dissecting the multiplicity of immune effects of immunosuppressive drugs to better predict the risk of de novo malignancies in solid organ transplant patients[J]. Front Oncol, 2019, 9: 160. DOI: 10.3389/fonc.2019.00160.
[5]	ENGELS EA, PFEIFFER RM, FRAUMENI JF JR, et al. Spectrum of cancer risk among US solid organ transplant recipients[J]. JAMA, 2011, 306(17): 1891-1901. DOI: 10.1001/jama.2011.1592.
[6]	KATABATHINA VS, MENIAS CO, TAMMISETTI VS, et al. Malignancy after solid organ transplantation: comprehensive imaging review[J]. Radiographics, 2016, 36(5): 1390-1407. DOI: 10.1148/rg.2016150175.
[7]	ROSSI AP, KLEIN CL. Posttransplant malignancy[J]. Surg Clin North Am, 2019, 99(1): 49-64. DOI: 10.1016/j.suc.2018.09.004.
[8]	ECCHER A, GIROLAMI I, MOTTER JD, et al. Donor-transmitted cancer in kidney transplant recipients: a systematic review[J]. J Nephrol, 2020, 33(6): 1321-1332. DOI: 10.1007/s40620-020-00775-4.
[9]	MYRON KAUFFMAN H, MCBRIDE MA, CHERIKH WS, et al. Transplant tumor registry: donor related malignancies[J]. Transplantation, 2002, 74(3): 358-362. DOI: 10.1097/00007890-200208150-00011.
[10]	SCHWARZ EI, VRUGT B, HUBER LC, et al. Development of allograft cancer after lung transplantation: a case report[J]. Ann Thorac Cardiovasc Surg, 2017, 23(4): 196-199. DOI: 10.5761/atcs.cr.16-00221.
[11]	RODRIGUES D, BORRO JM, AMADO J, et al. Metachronous pulmonary neoplasms in lung transplantation-when they arise in the donor lung: a case report[J]. Transplant Proc, 2018, 50(10): 4075-4079. DOI: 10.1016/j.transproceed.2018.08.051.
[12]	QUE SKT, ZWALD FO, SCHMULTS CD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors[J]. J Am Acad Dermatol, 2018, 78(2): 249-261. DOI: 10.1016/j.jaad.2017.08.058.
[13]	ELNAHAS S, OLSON MT, KANG P, et al. Factors associated with skin cancer in lung transplant recipients: a single-center experience[J]. Clin Transplant, 2019, 33(12): e13718. DOI: 10.1111/ctr.13718.
[14]	CORCHADO-COBOS R, GARCÍA-SANCHA N, GONZÁLEZ-SARMIENTO R, et al. Cutaneous squamous cell carcinoma: from biology to therapy[J]. Int J Mol Sci, 2020, 21(8): 2956. DOI: 10.3390/ijms21082956.
[15]	INMAN GJ, WANG J, NAGANO A, et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature[J]. Nat Commun, 2018, 9(1): 3667. DOI: 10.1038/s41467-018-06027-1.
[16]	D'ARCY ME, PFEIFFER RM, RIVERA DR, et al. Voriconazole and the risk of keratinocyte carcinomas among lung transplant recipients in the United States[J]. JAMA Dermatol, 2020, 156(7): 772-779. DOI: 10.1001/jamadermatol.2020.1141.
[17]	ONA K, OH DH. Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A[J]. Br J Dermatol, 2015, 173(3): 751-759. DOI: 10.1111/bjd.13862.
[18]	BASU P, GOLDENBERG A, COWAN N, et al. A 4-year retrospective assessment of postoperative complications in immunosuppressed patients following Mohs micrographic surgery[J]. J Am Acad Dermatol, 2019, 80(6): 1594-1601. DOI: 10.1016/j.jaad.2018.11.032.
[19]	FRAMPTON JE, BASSET-SÉGUIN N. Vismodegib: a review in advanced basal cell carcinoma[J]. Drugs, 2018, 78(11): 1145-1156. DOI: 10.1007/s40265-018-0948-9.
[20]	BRANDT MG, MOORE CC. Nonmelanoma skin cancer[J]. Facial Plast Surg Clin North Am, 2019, 27(1): 1-13. DOI: 10.1016/j.fsc.2018.08.001.
[21]	MIGDEN MR, RISCHIN D, SCHMULTS CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma[J]. N Engl J Med, 2018, 379(4): 341-351. DOI: 10.1056/NEJMoa1805131.
[22]	ZAFFIRI L, LONG A, NEELY ML, et al. Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: analysis of ISHLT Registry[J]. J Heart Lung Transplant, 2020, 39(10): 1089-1099. DOI: 10.1016/j.healun.2020.06.010.
[23]	GREWAL HS, LANE C, HIGHLAND KB, et al. Post-transplant lymphoproliferative disorder of the bladder in a lung transplant recipient[J]. Oxf Med Case Reports, 2018(3): omx093. DOI: 10.1093/omcr/omx093.
[24]	HAJI HA, CORWIN DS, SO JY, et al. Lymphoproliferative disorder in a lung transplant recipient[J]. BMJ Case Rep, 2020, 13(3): e234532. DOI: 10.1136/bcr-2020-234532.
[25]	LEYSSENS A, DIERICKX D, VERBEKEN EK, et al. Post-transplant lymphoproliferative disease in lung transplantation: a nested case-control study[J]. Clin Transplant, 2017, 31(7). DOI: 10.1111/ctr.12983.
[26]	KUMARASINGHE G, LAVEE O, PARKER A, et al. Post-transplant lymphoproliferative disease in heart and lung transplantation: defining risk and prognostic factors[J]. J Heart Lung Transplant, 2015, 34(11): 1406-1414. DOI: 10.1016/j.healun.2015.05.021.
[27]	LONG HM, MECKIFF BJ, TAYLOR GS. The T-cell response to Epstein-Barr virus-new tricks from an old dog[J]. Front Immunol, 2019, 10: 2193. DOI: 10.3389/fimmu.2019.02193.
[28]	PROCKOP SE, VATSAYAN A. Epstein-Barr virus lymphoproliferative disease after solid organ transplantation[J]. Cytotherapy, 2017, 19(11): 1270-1283. DOI: 10.1016/j.jcyt.2017.08.010.
[29]	HUANG S, YASUDA T. Pathologically relevant mouse models for Epstein-Barr virus-associated B cell lymphoma[J]. Front Immunol, 2021, 12: 639844. DOI: 10.3389/fimmu.2021.639844.
[30]	GOTTI E, REMUZZI G. Post-transplant Kaposi's sarcoma[J]. J Am Soc Nephrol, 1997, 8(1): 130-137. DOI: 10.1681/ASN.V81130.
[31]	NAGLE SJ, RESHEF R, TSAI DE. Posttransplant lymphoproliferative disorder in solid organ and hematopoietic stem cell transplantation[J]. Clin Chest Med, 2017, 38(4): 771-783. DOI: 10.1016/j.ccm.2017.08.001.
[32]	PRAKASH K, CHANDORKAR A, SAHARIA KK. Utility of CMV-specific immune monitoring for the management of CMV in solid organ transplant recipients: a clinical update[J]. Diagnostics (Basel), 2021, 11(5): 875. DOI: 10.3390/diagnostics11050875.
[33]	KIM N, SOHN HJ, OH JH, et al. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases[J]. Int J Hematol, 2018, 107(5): 596-603. DOI: 10.1007/s12185-017-2381-3.
[34]	PÉREZ-CALLEJO D, TORRENTE M, PAREJO C, et al. Lung cancer in lung transplantation: incidence and outcome[J]. Postgrad Med J, 2018, 94(1107): 15-19. DOI: 10.1136/postgradmedj-2017-134868.
[35]	TRIPLETTE M, CROTHERS K, MAHALE P, et al. Risk of lung cancer in lung transplant recipients in the United States[J]. Am J Transplant, 2019, 19(5): 1478-1490. DOI: 10.1111/ajt.15181.
[36]	ROBBINS HY, ARCASOY SM. Malignancies following lung transplantation[J]. Clin Chest Med, 2011, 32(2): 343-355. DOI: 10.1016/j.ccm.2011.02.011.
[37]	BROWN SW, DOBELLE M, PADILLA M, et al. Idiopathic pulmonary fibrosis and lung cancer. a systematic review and Meta-analysis[J]. Ann Am Thorac Soc, 2019, 16(8): 1041-1051. DOI: 10.1513/AnnalsATS.201807-481OC.
[38]	OLLAND AB, FALCOZ PE, SANTELMO N, et al. Primary lung cancer in lung transplant recipients[J]. Ann Thorac Surg, 2014, 98(1): 362-371. DOI: 10.1016/j.athoracsur.2014.04.014.
[39]	FACCIOLI E, DELL'AMORE A, SCHIAVON M, et al. Successful lung transplantation in a patient with history of lobectomy for small cell lung cancer: a case report[J]. Transplant Proc, 2021, 53(4): 1382-1384. DOI: 10.1016/j.transproceed.2021.03.016.
[40]	VAN RAEMDONCK D, VOS R, YSERBYT J, et al. Lung cancer: a rare indication for, but frequent complication after lung transplantation[J]. J Thorac Dis, 2016, 8(Suppl 11): S915-S924. DOI: 10.21037/jtd.2016.11.05.
[41]	TIAN T, LI X, ZHANG J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy[J]. Int J Mol Sci, 2019, 20(3): 755. DOI: 10.3390/ijms20030755.
[42]	VICARY GW, ROMAN J. Targeting the mammalian target of rapamycin in lung cancer[J]. Am J Med Sci, 2016, 352(5): 507-516. DOI: 10.1016/j.amjms.2016.08.014.
[43]	ASSI HI, KAMPHORST AO, MOUKALLED NM, et al. Immune checkpoint inhibitors in advanced non-small cell lung cancer[J]. Cancer, 2018, 124(2): 248-261. DOI: 10.1002/cncr.31105.
[44]	ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1): 106. DOI: 10.1186/s40425-019-0585-1.
[45]	WONG G, AU E, BADVE SV, et al. Breast cancer and transplantation[J]. Am J Transplant, 2017, 17(9): 2243-2253. DOI: 10.1111/ajt.14368.
[46]	MEYER KC, FRANCOIS ML, THOMAS HK, et al. Colon cancer in lung transplant recipients with CF: increased risk and results of screening[J]. J Cyst Fibros, 2011, 10(5): 366-369. DOI: 10.1016/j.jcf.2011.05.003.
[47]	NA R, LAAKSONEN MA, GRULICH AE, et al. High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: a population-based cohort study[J]. J Am Acad Dermatol, 2016, 74(6): 1144-1152. DOI: 10.1016/j.jaad.2015.12.044.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (461) PDF downloads(87)

Research progress on malignant tumor after lung transplantation

doi: 10.3969/j.issn.1674-7445.2021.05.019

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research progress on malignant tumor after lung transplantation

doi: 10.3969/j.issn.1674-7445.2021.05.019

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content